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Juggling Art: Making Critical Clinical Decisions without Vital Laboratory 
Support in Autoimmune Rheumatic Patients in a Resource Poor Setting 
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Introduction 
Laboratory testing is essential when assessing a patient 
with a suspected autoimmune rheumatic disease. The 
results can confirm the possible diagnosis, evaluate dis-
ease severity, its complications, and assist in determin-
ing the prognosis as well as monitor future disease ac-
tivity of patients. Systemic autoimmune rheumatic con-
ditions like Systemic lupus erythematous (SLE) or 
Rheumatoid arthritis (RA) can be difficult to diagnose 
as they mimic themselves and other medical conditions. 
 
Diagnosis 
There are well established criteria for the diagnosis of 
SLE1 and RA.2 Diagnosing an autoimmune condition 
can be challenging and it is reported that on average  
patients may take up to 4 years before diagnosis is made 
even in resource rich countries. In Ghana, average dis-
ease duration before diagnosis in SLE patients was re-
ported by Dey et al to be about 53.6 weeks range <1 – 
380 weeks.3 
 
Superior diagnostic techniques are essential for early 
diagnosis. Given the myriad of symptoms which mimic 
other conditions, symptoms that overlap especially in 
the early stages, and the fact that many patients have 
more than one condition concurrently, the detection and 
use of autoantibodies is an essential element in making 
a timely and accurate diagnosis. 
 
 
Table 1 Laboratory Tests for Classification, Diagnosis and Prognosis of Autoimmune Rheumatic 
Rheumatoid Arthritis (RA) 
Rheumatoid Factor (IgG) diagnoses RA; provides added specificity when used in combination 
with other RF or (cyclic citrullinated antibodies) CCP antibody assays 
Anti CCP antibodies diagnoses RA and determines prognosis 
ESR and CRP for determining disease activity 
Sarcoidosis 
Angiotensin Converting Enzyme (ACE) supports diagnosis of sarcoidosis 
High serum Calcium supports diagnosis of sarcoidosis 
Calcium, 24-Hour Urine with Creatinine support diagnosis of sarcoidosis and renal involvement 
FBC  (Full blood count includes Differential and Platelets) support diagnosis of sarcoidosis 
Sjögren’s Syndrome 
ANA(Antinuclear antibody) screen  
Rheumatoid factor 
SS-A and SS-B antibodies. 
Systemic Lupus Erythematosus 
 ANA screen  
Other antibodies: Chromatin (nucleosomal), dsDNA,(double stranded Deoxyribonucleic acid) 
anti Sm(Smith) antibodies, ribosomal –p, Scl-70, RNP(ribonucleoprotein), SS-A, and SS-B anti-
bodies 
Complement components C3 and C4 and total complement (CH50). 
Lupus Anticoagulant and Antiphospholipid 
Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM)  
Cardiolipin Antibodies (IgA, IgG, IgM)  
Direct Antiglobulin Test (DAT) determines presence of autoimmune hemolytic anemia 
Platelet Antibody, Direct (IgG) detects autoimmune thrombocytopenia 
Ribosomal P Antibody diagnose neuropsychiatric SLE 
RNP Antibody diagnose SLE or MCTD (mixed connective tissue  disease) 
White Blood Cell Count (WBC) determine presence of leucopenia 
Kidney biopsy for diagnosis, staging of lupus nephritis and prognosis 
anti-C1q antibodies predict development of kidney disease in SLE 
Systemic Sclerosis 
Centromere B Antibody diagnose limited cutaneous systemic sclerosis (CREST) 
RNA Polymerase III Antibody, Scleroderma Antibody (Scl-70) diagnose systemic sclerosis 
Systemic Vasculitis 
ANCA (Anti-nuclear cytoplasmic antibody )screen with MPO(myeloperoxidase) and 
PR3(proteinase 3) differentiate types of systemic vasculitis 
C-Reactive Protein (CRP) identify inflammatory  or active conditions 
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A timely diagnosis offers the prospect of early therapeu-
tic action, which can often slow (e.g., erosion of joints 
in RA) or even halt disease progression (e.g., undiffer-
entiated connective tissue disease or lupus). Early 
treatment of these conditions reduces long term damage 
and its attendant health care costs.4 
 
The great advances made in autoantibody testing over 
the last two decades make it possible to use specific 
autoantibody markers to increase diagnostic precision in 
systemic autoimmune diseases. New diagnostic tech-
nologies enabling screening for multiple autoantibodies 
(Refer to Table 1) whose pattern make it possible to 
diagnose autoimmune diseases earlier and to intervene 
before serious end organ damage occurs.5 
 
Prognosis  
In patients with known or suspected systemic autoim-
mune disease, a panel of disease-specific markers is also 
useful in assessing prognosis. These disease markers 
make it possible to tell what possible complications may 
occur with the disease e.g. anti-C1q antibodies predict 
development of kidney disease in SLE(Refer to Table 1)  
and make for better monitoring and treatment tailored to 
the patient.6 Biomarkers hold the promise of revolution-
izing the management of autoimmune rheumatic condi-
tions by enabling early diagnosis, rapid assessment and 
prediction of disease severity, personalized choice of 
therapy, and monitoring of response to therapy. The use 
of biomarkers for the early detection of autoimmune 
disease can result in safer and better treatments with 
fewer side effects for patients and the efficient use of 
drugs as they are tailored to the patient’s unique immu-
nologic and clinical features thus reducing side effects, 
saving cost and promoting the judicious use of 
healthcare resources.7 
 
Need for improved timely laboratories 
In Ghana and indeed most of sub-Saharan Africa, there 
is undue delay in obtaining serology test results because 
samples have to be sent outside the country to accredit-
ed laboratories in e.g. Germany and South Africa. On 
average it takes two (sometime three) weeks to obtain 
these vital antibody tests. This imposes delays in estab-
lishing a diagnosis, establishing critical organ involve-
ment and differentiating between a flare-up and an in-
fective process. This situation ultimately then affects the 
selection of appropriate therapeutic interventions.  
 
These tests also come at huge costs. On average to 
complete a set of tests for a patient with, for example, 
SLE will cost about GHC 2000.00 (Two thousand Gha-
na cedis) or approximately USD 500.00 (Five hundred 
US dollars) in a country where the minimum wage is 
about two US dollars a day.  
An audit of patient’s clinic reviews show a high attrition 
rate after these tests are requested as patients feel the 
need to complete tests ordered before coming back for 
subsequent reviews leading to further delays in treat-
ment. 
 
To make the best of the situation, emphasis is placed on 
the clinical features of these conditions and clinical 
judgment when arriving at a diagnosis. This approach is 
helpful for the more standard presentations of the dis-
eases, but when diagnosing patients with less distinctive 
features, most physicians get stuck with few differential 
diagnosis,. Indeed before investigations most referrals 
diagnose young females with small joint involvement as 
rheumatoid arthritis instead of SLE, as may be revealed 
later and to most trainees the foremost diagnosis for any 
one with joint pain is rheumatoid arthritis. 
 
Renal biopsy is an important tool in the diagnosis of 
lupus nephritis, this is needed to identify the histological 
class, determine activity and chronicity indices, detect 
clinically important non-glomerular lesions, and exclude 
other diagnoses or comorbidities8. A renal biopsy is 
needed as a definitive diagnosis of lupus nephritis. 
 
Histopathological analysis reports in Ghana takes up to 
three months to become available in some cases, though 
the technique of doing renal biopsies is readily availa-
ble, mainly because the samples are sent to the United 
Kingdom for analysis. We therefore speculate on the 
patient's likely renal pathology and move on to take 
therapeutic decisions. This could result in patients who 
are stages 1, II or V lupus nephritis who don’t need such 
intensive treatment being treated with drugs that have 
severe side effect profile. But for those with obviously 
severe renal disease taking this decision may not be 
such a risk and works in their favour. 
 
 In severe lupus nephritis cases , understanding the dis-
ease process together with some clinical and laboratory 
data is often enough to permit standard treatment de-
spite the absence of a renal biopsy.9 Monitoring sched-
ules are stretched out to reduce the financial burden on 
patients (e.g. doing serum complements levels only 
when essential to distinguish a flare rather than as rou-
tine and adjusting liver function tests when on metho-
trexate to be done in two weeks from the start and 
thereafter at every visit instead of every month until 
stable) 
 
 If the purpose of the laboratory is to aid the clinician in 
patient management, then it is usually essential that the 
methods of detecting autoantibodies are specific, sensi-
tive, reliable, reproducible and most importantly availa-
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In our case, cheap and timely maybe more important 
than up-to-date. The laboratory has an essential role in 
the proper management of the autoimmune rheumatic 
patient, we are however a long way from efficient use of 
this and must carry on the juggling art of conjuring a 
diagnosis mainly with clinical criterion, and developing 
our own ways of monitoring and treating our high risk 
patients bearing in mind the constraints and hoping for 
the best in the future, all the while pushing for more 
heath infrastructure development. 
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